Fmr LLC Purchases 47,075 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Fmr LLC raised its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 0.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,824,675 shares of the company’s stock after buying an additional 47,075 shares during the period. Fmr LLC owned about 0.15% of Janux Therapeutics worth $355,475,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of JANX. Summit Securities Group LLC purchased a new stake in Janux Therapeutics in the 2nd quarter worth $29,000. Amalgamated Bank increased its position in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the last quarter. Plato Investment Management Ltd purchased a new stake in shares of Janux Therapeutics during the 2nd quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. raised its position in Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Janux Therapeutics in the second quarter worth $151,000. 75.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JANX has been the topic of a number of research reports. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a research note on Thursday, November 7th. Scotiabank lowered their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. Finally, Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $67.70.

Insider Activity at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $42.00, for a total transaction of $4,551,330.00. Following the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. This trade represents a 3.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of the business’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares of the company’s stock, valued at approximately $3,106,528.32. The trade was a 42.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 445,610 shares of company stock worth $20,578,666. 29.40% of the stock is owned by insiders.

Janux Therapeutics Trading Down 2.5 %

Shares of JANX stock opened at $45.21 on Friday. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $65.60. The stock has a 50 day simple moving average of $49.81 and a 200-day simple moving average of $45.78. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -38.64 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Janux Therapeutics’s revenue for the quarter was down 82.6% compared to the same quarter last year. On average, equities analysts forecast that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.